Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

December interest rate cut uncertain: Fed governor
Finance

December interest rate cut uncertain: Fed governor

Lisa Cook says the timing of further reductions will depend on new data.

Bayly to banks: ‘Just get on with it’
Finance

Bayly to banks: ‘Just get on with it’

Minister Andrew Bayly is impatient for the changes needed to improve competition.

Ben Moore 20 Nov 2024
‘Regulatory failure’ let NZ’s payments fall behind
Finance

‘Regulatory failure’ let NZ’s payments fall behind

NZ was the All Blacks of payments, but now barely makes regionals as regulation lagged.

Ben Moore 19 Nov 2024